Sophia Antipolis, France – 28 Aug 2021: Ablation plus cardiac resynchronisation therapy (CRT) is superior to pharmacological rate control in reducing mortality in severely symptomatic permanent atrial fibrillation (AF) patients with a narrow QRS, according to late breaking research presented in a Hot Line session today at ESC Congress 20211 and published in the European Heart Journal.2
Previous research has shown that in patients with AF, atrioventricular (AV) junction ablation and right ventricular pacing improved symptoms, quality of life, and cardiac function by slowing and regularising the ventricular rate. However, the therapy failed to reduce mortality.3 The authors of the current trial previously demonstrated that biventricular pacing with CRT may counteract the adverse effects of non-physiological right ventricular pacing in AF patients.4
APAF-CRT was a two-phase trial in patients with severely symptomatic permanent AF and a narrow QRS. The first phase, focused on morbidity, showed that AV junction ablation and CRT reduced hospitalisation due to heart failure and improved heart failure symptoms compared with pharmacological rate control at two years of follow-up.5
Results of the second phase, focused on mortality, are presented today. In a larger population with a longer follow-up, the trial tested the hypothesis that AV junction ablation and biventricular pacing is superior to pharmacological rate control therapy in reducing all-cause mortality.
This was a multicentre, international, prospective, randomised, parallel, open-label trial with a blinded outcome. Patients were enrolled with the following inclusion criteria: severely symptomatic permanent AF (over six months) considered unsuitable for AF ablation or in whom AF ablation had failed; narrow QRS (110 ms or below); and at least one hospitalisation for heart failure in the previous year.
Patients were randomly assigned in a 1:1 fashion to AV junction ablation and biventricular pacing (ablation+CRT arm) or optimal pharmacological rate control therapy (drug arm). Patients in both arms could additionally be given a defibrillator at the discretion of their physician according to ESC guidelines.6
A total of 133 patients were randomised. The mean age was 73 years and 62 (47%) were women. The trial was stopped for efficacy at the interim analysis after a median of 29 months of follow-up per patient.
The primary endpoint of death from any cause occurred in seven patients (11%) in the ablation+CRT arm and in 20 patients (29%) in the drug arm (hazard ratio 0.26; 95% confidence interval [CI] 0.10–0.65; p=0.004). The estimated death rates at four years were 14% and 41% in the ablation+CRT and drug arms, respectively. At four years, the relative and absolute risk reductions were 74% and 27%, respectively, and the number needed to treat was 3.7.
Moreover, AV junction ablation and CRT reduced the secondary endpoint of the combined risks of death from any cause or hospitalisation for heart failure by 60% (95% CI 0.22–0.73; p=0.002).
Principal investigator Professor Michele Brignole of the IRCCS Istituto Auxologico Italiano, San Luca Hospital, Milan said: “We hypothesise that the observed benefit was due to the combination of the strict rate control and rate regularisation achieved by AV junction ablation, together with biventricular pacing which counteracted the adverse effects of right ventricular pacing. The improvement in survival shown by the APAF-CRT trial supports ablation plus CRT as a first line therapy in patients with permanent AF, narrow QRS and previous hospitalisation for heart failure.”
ENDS
Our mission: To reduce the burden of cardiovascular disease.